FAYE M JOHNSON to Camptothecin
This is a "connection" page, showing publications FAYE M JOHNSON has written about Camptothecin.
Connection Strength
0.870
-
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol. 2009 Oct; 6(10):562-3.
Score: 0.277
-
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):366-74.
Score: 0.214
-
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
Score: 0.180
-
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
Score: 0.180
-
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.
Score: 0.018